Johnson & Johnson developing stem cell cure for Type 1 diabetes


Johnson & Johnson and biotech company ViaCyte are exploring a possible cure for Type 1 diabetes with encouraging results, The Associated Press reports. The stem cell treatment involves turning embryotic stem cells into insulin-producing cells in a lab, and then putting them in a small capsule to implant under a patient's skin.
Patients with Type 1 diabetes cannot produce insulin. In a healthy person, insulin is made by the body in response to rising blood sugar levels after a meal. High levels of sugar in the bloodstream can lead to the damage of blood vessels, organs, and can even kill patients. Type 1 diabetes patients need to take frequent insulin injections as a result — something the insulin-implant produced by ViaCyte and Johnson & Johnson would render unnecessary.
Testing began on patients a year ago; they received a small dose of the insulin-producing cells in their implants and are to be closely monitored for two years. The companies reported that after 12 weeks, the patient's devices were working as expected with no side effects observed. Another several rounds of patient testing are expected before regulators will approve the device.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
About 29.1 million Americans have diabetes, which includes 1.25 million with Type 1, or insulin-dependent, diabetes. Type 2 diabetics — whose bodies make insulin but use it ineffectively — are on the rise, as are Type 1 diabetics. Current treatment includes a strict diet, exercise, and multiple daily insulin injections and finger-prick blood tests.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Jeva Lange was the executive editor at TheWeek.com. She formerly served as The Week's deputy editor and culture critic. She is also a contributor to Screen Slate, and her writing has appeared in The New York Daily News, The Awl, Vice, and Gothamist, among other publications. Jeva lives in New York City. Follow her on Twitter.
-
Israel, Hamas agree to first step of Trump peace plan
Speed Read Israel’s military pulls back in Gaza amid prisoner exchange
-
Israel intercepts 2nd Gaza aid flotilla in a week
Speed Read The Israeli military intercepted a flotilla of nine boats with 145 activists aboard along with medical and food aid
-
Japan poised to get first woman prime minister
Speed Read The ruling Liberal Democratic Party elected former Economic Security Minister Sanae Takaichi
-
Israel and Hamas meet on hostages, Trump’s plan
Speed Read Hamas accepted the general terms of Trump’s 20-point plan, including the release of all remaining hostages
-
US tipped to help Kyiv strike Russian energy sites
Speed Read Trump has approved providing Ukraine with intelligence for missile strikes on Russian energy infrastructure
-
Netanyahu agrees to Trump’s new Gaza peace plan
Speed Read At President Trump's meeting with Israeli Prime Minister Benjamin Netanyahu, they agreed upon a plan to end Israel’s war in Gaza
-
Russia is ‘helping China’ prepare for an invasion of Taiwan
In the Spotlight Russia is reportedly allowing China access to military training
-
Moldova gives decisive win to pro-EU party
Speed Read The country is now on track to join the European Union within five years